Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pancreatitis II: Pathophysiology01:21

Acute Pancreatitis II: Pathophysiology

The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival Outcomes of Gemcitabine-Cisplatin-S-1 Versus Gemcitabine-Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery.

Annals of gastroenterological surgery·2026
Same author

A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial.

Liver cancer·2026
Same author

Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.

Journal of gastroenterology·2026
Same author

Impact of Germline <i>BRCA</i> Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis.

JCO precision oncology·2026
Same author

Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab.

Cancers·2025
Same author

Conversion Surgery after Complete Response to Immune Checkpoint Inhibitor-Based Sequential Chemotherapy for Initially Unresectable Perihilar Cholangiocarcinoma: A Case Report.

Surgical case reports·2025

Related Experiment Video

Updated: Jul 16, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Hypercoagulability Predicts Survival and Reflects NET-Associated Thromboinflammation in Advanced Pancreatic Cancer.

Lingaku Lee1, Masami Miki1, Masayuki Hijioka1

  • 1Department of Hepato-Biliary-Pancreatology, NHO Kyushu Cancer Center, Fukuoka 811-1395, Japan.

Cancers
|July 15, 2026
PubMed
Summary

In advanced pancreatic cancer, hypercoagulability, not overt thrombosis, predicts survival. Monitoring and managing hypercoagulability may improve patient outcomes and risk stratification.

Keywords:
advanced pancreatic cancercancer-associated thrombosishypercoagulabilityneutrophil extracellular trapsvenous thromboembolism

More Related Videos

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

Related Experiment Videos

Last Updated: Jul 16, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

Area of Science:

  • Oncology
  • Hematology
  • Thrombosis Research

Background:

  • Cancer-associated thrombosis is a significant complication in pancreatic cancer, but its full impact and prognostic value are unclear due to under-detection of asymptomatic events.
  • The roles of cancer-related hypercoagulability and neutrophil extracellular traps (NETs) in linking thrombosis and tumor biology require further evaluation in advanced pancreatic cancer.

Purpose of the Study:

  • To prospectively investigate the prevalence and prognostic significance of venous thromboembolism (VTE) in patients with advanced pancreatic cancer.
  • To evaluate the association between hypercoagulability, NET-related biomarkers, VTE, and overall survival (OS) in this patient population.

Main Methods:

  • Prospective study of 134 newly diagnosed patients with unresectable pancreatic ductal adenocarcinoma.
  • Systematic screening for VTE at baseline and longitudinal surveillance.
  • Analysis of circulating coagulation markers, NET-related biomarkers, and association with OS.

Main Results:

  • VTE was detected at diagnosis in 28.4% of patients, mostly asymptomatic. Hypercoagulability and NET biomarkers correlated with VTE.
  • Patients with baseline VTE or hypercoagulability had significantly shorter OS (6.2 and 7.7 months, respectively).
  • Hypercoagulability independently predicted inferior OS (HR 2.03), while baseline VTE did not. Reduction in D-dimer levels correlated with improved survival.

Conclusions:

  • Hypercoagulability, rather than overt VTE, is an independent predictor of survival in advanced pancreatic cancer.
  • These findings suggest a biology-driven approach to thrombosis assessment in pancreatic cancer.
  • Monitoring and therapeutic modulation of hypercoagulability may enhance risk stratification and clinical management.